Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans

There is no clinically applicable biomarker for surveillance of hepatocellular carcinoma (HCC), because the sensitivity of serum alpha‐fetoprotein (AFP) is too low for this purpose. Here, we determined the diagnostic performance of a panel of urinary metabolites of HCC patients from West Africa. Urine samples were collected from Nigerian and Gambian patients recruited on the case‐control platform of the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) program. Urinary proton nuclear magnetic resonance (1H‐NMR) spectroscopy was used to metabolically phenotype 290 subjects: 63 with HCC; 32 with cirrhosis (Cir); 107 with noncirrhotic liver disease (DC); and 88 normal control (NC) healthy volunteers. Urine samples from a further cohort of 463 subjects (141 HCC, 56 Cir, 178 DC, and 88 NC) were analyzed, the results of which validated the initial cohort. The urinary metabotype of patients with HCC was distinct from those with Cir, DC, and NC with areas under the receiver operating characteristic (AUROC) curves of 0.86 (0.78‐0.94), 0.93 (0.89‐0.97), and 0.89 (0.80‐0.98) in the training set and 0.81 (0.73‐0.89), 0.96 (0.94‐0.99), and 0.90 (0.85‐0.96), respectively, in the validation cohort. A urinary metabolite panel, comprising inosine, indole‐3‐acetate, galactose, and an N‐acetylated amino acid (NAA), showed a high sensitivity (86.9% [75.8‐94.2]) and specificity (90.3% [74.2‐98.0]) in the discrimination of HCC from cirrhosis, a finding that was corroborated in a validation cohort (AUROC: urinary panel = 0.72; AFP = 0.58). Metabolites that were significantly increased in urine of HCC patients, and which correlated with clinical stage of HCC, were NAA, dimethylglycine, 1‐methylnicotinamide, methionine, acetylcarnitine, 2‐oxoglutarate, choline, and creatine. Conclusion: The urinary metabotyping of this West African cohort identified and validated a metabolite panel that diagnostically outperforms serum AFP. (Hepatology 2014;60:1291–1301)

[1]  N. Chavez-Tapia,et al.  Clinical practice guidelines: Management of Hepatocellular Carcinoma , 2014 .

[2]  J. Suo,et al.  The endothelial lipase protein is promising urinary biomarker for diagnosis of gastric cancer , 2013, Diagnostic Pathology.

[3]  Hui Sun,et al.  Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquid-chromatography coupled with high-definition mass spectrometry. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[4]  Ara W. Darzi,et al.  Metabolic phenotyping in clinical and surgical environments , 2012, Nature.

[5]  F. Sotgia,et al.  Ketone body utilization drives tumor growth and metastasis , 2012, Cell cycle.

[6]  Xin Lu,et al.  Analysis of urinary metabolic signatures of early hepatocellular carcinoma recurrence after surgical removal using gas chromatography-mass spectrometry. , 2012, Journal of proteome research.

[7]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[8]  J. Lindon,et al.  Stability and robustness of human metabolic phenotypes in response to sequential food challenges. , 2012, Journal of proteome research.

[9]  V. Mazzaferro,et al.  EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer , 2012 .

[10]  S. Doniņa,et al.  Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer: a case--control study. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[11]  R. Franklin,et al.  The genetic/metabolic transformation concept of carcinogenesis , 2012, Cancer and Metastasis Reviews.

[12]  Z. Bhujwalla,et al.  Choline metabolism in malignant transformation , 2011, Nature Reviews Cancer.

[13]  Yongzhang,et al.  Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases , 2011 .

[14]  Zhi Chen,et al.  Revised Papers , 2022 .

[15]  Ping Liu,et al.  Serum and Urine Metabolite Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma* , 2011, Molecular & Cellular Proteomics.

[16]  Lanjuan Li,et al.  Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry. , 2011, Analytica chimica acta.

[17]  H. Thomas,et al.  Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. , 2011, Journal of proteome research.

[18]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[19]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[20]  P. Malfertheiner,et al.  World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. , 2010, Journal of gastrointestinal and liver diseases : JGLD.

[21]  H. Thomas,et al.  Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. , 2010, Journal of proteome research.

[22]  T. Manini,et al.  Sarcopenia: Clinical evaluation, biological markers and other evaluation tools , 2009, The journal of nutrition, health & aging.

[23]  Tao-Tao Liu,et al.  Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. , 2009, Analytica chimica acta.

[24]  Xin Lu,et al.  A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. , 2009, Molecular bioSystems.

[25]  T. Ebbels,et al.  Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts , 2007, Nature Protocols.

[26]  H. El‐Serag Epidemiology of hepatocellular carcinoma in USA , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[27]  Yong Yue,et al.  Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. , 2007, Journal of proteome research.

[28]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[29]  N. Anderson,et al.  A List of Candidate Cancer Biomarkers for Targeted Proteomics , 2006, Biomarker insights.

[30]  D. Parkin,et al.  The global health burden of infection‐associated cancers in the year 2002 , 2006, International journal of cancer.

[31]  Henrik Antti,et al.  Comparative metabonomics of differential hydrazine toxicity in the rat and mouse. , 2005, Toxicology and applied pharmacology.

[32]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[33]  D. Gauguier,et al.  Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. , 2005, Analytical chemistry.

[34]  B. Daniele,et al.  α-fetoprotein and ultrasonography screening for hepatocellular carcinoma , 2004 .

[35]  H. El‐Serag,et al.  Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. , 2004, Gastroenterology.

[36]  B. Daniele,et al.  Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. , 2004, Gastroenterology.

[37]  H. Thomas,et al.  Changing international trends in mortality rates for liver, biliary and pancreatic tumours. , 2002, Journal of hepatology.

[38]  J. Bruix,et al.  Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.

[39]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[40]  Jimmy D Bell,et al.  Metabolic changes underlying 31P MR spectral alterations in human hepatic tumours , 1998, NMR in biomedicine.

[41]  M. Spraul,et al.  750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. , 1995, Analytical chemistry.